Nusrath Sultana M.D. serves as Vice President - Clinical Affairs of the Company. She brings more than 20 years of medical affairs, medtech, and healthcare experience. Prior to joining Surmodics, she served as Senior Director, Global Medical Affairs at Edwards Lifesciences, a global leader in patient-focused medical innovations for structural heart disease, as well as critical care and surgical monitoring. Sultana was responsible for the development of medical affairs infrastructure and provided leadership, oversight and strategic direction for core medical affairs activities. Prior to her time at Edwards Lifesciences, Sultana held numerous positions—most recently Senior Director, Global Clinical Operations—at St. Jude Medical. She holds an MD from Deccan College of Medical Science in Hyderabad, India, and an MBA in Medical Group Management from the University of St. Thomas in St. Paul, Minnesota.
Nusrath's mailing address filed with the SEC is 9924, West 74th Street, Eden Prairie, Hennepin County, Minnesota, 55344, United States of America.
Over the last 21 years, insiders at Surmodics have traded over 26,204,565$ worth of Surmodics stock and bought 19,725 units worth 436,251$ . The most active insiders traders include Jeffrey C Smith、Gary R Maharaj、Value Lp Starboard Value Gp.... On average, Surmodics executives and independent directors trade stock every 34 days with the average trade being worth of 415,014$. The most recent stock trade was executed by Joseph J. Stich on 21 August 2024, trading 21,285 units of SRDX stock currently worth 706,662$.
surmodics partners with the world's leading and emerging medical device, diagnostic and life sciences companies to develop and commercialize innovative products designed to improve lives by enabling the detection and treatment of disease. following two recent acquisitions, the company is transforming its medical device business from being a provider of coating technologies, to offering whole-product solutions. throughout its transformation, surmodics’ mission remains: to improve the detection and treatment of disease by using our technology to provide solutions to difficult medical device and diagnostic challenges.
Surmodics executives and other stock owners filed with the SEC include: